Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.

dc.contributor.authorPérez-Ruiz, Elisabeth
dc.contributor.authorEtxeberria, Iñaki
dc.contributor.authorRodriguez-Ruiz, Maria E
dc.contributor.authorMelero, Ignacio
dc.date.accessioned2025-01-07T14:53:17Z
dc.date.available2025-01-07T14:53:17Z
dc.date.issued2017-08-08
dc.description.abstractT-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.
dc.identifier.doi10.1158/1078-0432.CCR-17-1799
dc.identifier.essn1557-3265
dc.identifier.pmid28790118
dc.identifier.urihttps://hdl.handle.net/10668/26705
dc.issue.number18
dc.journal.titleClinical cancer research : an official journal of the American Association for Cancer Research
dc.journal.titleabbreviationClin Cancer Res
dc.language.isoen
dc.organizationSAS - Hospital Costa del Sol
dc.page.number5326-5328
dc.pubmedtypeLetter
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshB7-H1 Antigen
dc.subject.meshClinical Trials, Phase I as Topic
dc.subject.meshDrug Synergism
dc.subject.meshHumans
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshNeoplasms
dc.subject.meshProgrammed Cell Death 1 Receptor
dc.subject.meshTreatment Outcome
dc.subject.meshTumor Necrosis Factor Receptor Superfamily, Member 9
dc.titleAnti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
dc.typeresearch article
dc.volume.number23

Files